Loading...
Respiratory syncytial virus (RSV) vaccines became available only last year (in 2023), and the protocols for their use still are evolving. Two new studies might help clinicians manage winter 2024–2025 vaccinations more confidently.
Researchers prospectively analyzed hospitalizations in a single New York county during 2017 to 2020 and calculated population-based rates of severe RSV. Among community-dwelling older adults, rates of infection requiring hospitalization rose from 91 per 100,000 (for ages 65–74) to 191 per 100,000 (for ages ≥85). These rates were dwarfed by rates among older adults (age, ≥65) who lived in assisted living or skilled nursing facilities (738 and 439 per 100,000, respectively). The authors ascribe the especially high ra…